Biogen Enters Exclusive Option Agreement To Acquire TMS' Phase 2 Asset For Acute Stroke; Co. To Pay $4M Upfront And $18M Upon Exercise Of Option And Potential Milestones Of Up To $335M
Benzinga Newsdesk